RxDoctor Payments Data

Martha Root

Psychiatric/Mental Health · Lowell, MANPI 1730339045

Payments from drug & device makers

$1,970in general payments, 2019–2025

Across 29 payments — averaging $67.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$410
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$391
  • Neurocrine Biosciences, Inc.$304
  • E.r. Squibb & Sons, L.L.C.$247
  • Idorsia Pharmaceuticals US Inc$125
  • AbbVie$124
  • plus $370 from 5 others

What the payments were for

  • Food & beverage$1,88195%
  • Education$895%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,970 in reported general payments places this provider in the 85th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$30,129
Medicare patients
37
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole12$24,619
VyvanseLisdexamfetamine Dimesylate21$8,664
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine150$2,676
Trazodone Hcl97$2,042
Quetiapine Fumarate41$1,752
Duloxetine Hcl59$1,630
Lamotrigine107$1,418
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine36$1,295
Gabapentin51$1,166
Methylphenidate ErMethylphenidate Hcl11$1,098
Aripiprazole36$1,059
Clonazepam136$1,025
Bupropion Hcl SrBupropion Hcl30$966
Venlafaxine Hcl ErVenlafaxine Hcl14$962
Fluvoxamine Maleate27$835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$410$24,61912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Lowell

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →